OPKO Health Inc ( OPKO)

Primary tabs

OPKO's picture

Management

Contact Address

About OPKO Health Inc

OPKO Health, Inc. is a multinational pharmaceutical & diagnostics company aiming to establish leading positions in large & rapidly growing medical markets.

OPKO press release, blog etc

Fri, 04/04/2025 - 18:17 OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program
Mon, 03/17/2025 - 11:16 OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
Tue, 03/11/2025 - 11:16 Labcorp Announces Acquisition of Select Assets of BioReference Healths Innovative Oncology and Related Clinical Testing Services Businesses
Tue, 10/08/2024 - 07:21 ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program
Sat, 07/20/2024 - 02:22 OPKO Health Announces $100 Million Share Repurchase Program
Wed, 07/17/2024 - 17:45 OPKO Health and HealthCare Royalty Enter into $250 Million Note Purchase Agreement Secured by NGENLAs Profit Share Payments
Mon, 05/02/2022 - 12:23 Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
Thu, 02/03/2022 - 16:43 RAYALDEE Launched in Germany by OPKO Healths Licensee, VFMCRP
Thu, 12/23/2021 - 11:40 OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients
Wed, 12/08/2021 - 17:32 OPKO Health Receives U.S. FDA Approval for the 4Kscore Test
Mon, 12/06/2021 - 06:30 OPKO Health Announces the Passing of Director Dr. Richard Lerner
Sun, 11/28/2021 - 21:07 BioReference Laboratories Announces Readiness for COVID-19 Testing if the Omicron COVID-19 Variant Emerges in The U.S.
Tue, 09/14/2021 - 13:55 LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories
Mon, 08/30/2021 - 13:22 OPKO Health to Participate in Two Upcoming Investment Conferences
Mon, 08/30/2021 - 13:08 OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients
Mon, 08/16/2021 - 14:51 BioReference Laboratories Acquires U.S. Ariosa Centralized Laboratory Prenatal Testing Business
Mon, 07/12/2021 - 13:33 OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
Tue, 02/05/2019 - 13:11 OPKO Health, Inc. Announces the Pricing of its Offering of Convertible Senior Notes
more

InfoBox

HomePagewww.opko.com
Wikipediaen.wikipedia.org/wiki/OPKO_Health